Enabling patient-centric trials
Clinical trials have been primarily driven by a site-centric approach (such as face-to-face interactions at the site).
The COVID-19 pandemic severely impacted the functioning of traditional clinical trials and opened a world of possibilities to move to the next generation of clinical trials. Augmented by digital technologies, clinical trials improve participant access, engagement enabling patient-centricity.
Merck partnered with TCS to realize its vision of a digitally enabled trials platform (DETP), leveraging TCS ADD’s decentralized trials solution. The DETP was aimed at resolving challenges around protocol impact, supplier qualification and GxP procedures, managing data privacy, and calculating RoI.
The partnership facilitated a host of features being actively tested, viz-a-viz, electronic date capture from device and reporting, auto reminders, interim data storage, API, passive data transfer, and BYOD.